Tirzepatide: Dual GIP/GLP-1 Receptor Agonist Research Overview

Tirzepatide is a synthetic peptide developed under the code LY3298176 and described in the literature as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Its design combines incretin receptor engagement with structural modification intended to support once-weekly dosing in the clinical programs where it was studied.

Manufacturer and regulatory labeling describe tirzepatide with the molecular formula C225H348N48O68 and a molecular weight of approximately 4813.5 g/mol. That figure comes from labeling rather than from an independent analytical determination; the molecular weight reported on a specific lot's certificate is the value that describes the material in hand.

GLP-1 receptor agonism is the more extensively characterized of the two pathways and is associated in published work with glucose-dependent insulin release, slowed gastric emptying, and central satiety signaling. GIP receptor agonism has been studied both for its own incretin effect and for how it modifies GLP-1 receptor-driven responses.

The dual-agonist hypothesis in the literature is that engaging both receptors yields a metabolic profile distinguishable from GLP-1 receptor agonism alone. Comparative trial data have been used to examine that hypothesis directly.

The SURPASS program studied tirzepatide in type 2 diabetes. SURPASS-2, published in the New England Journal of Medicine in 2021, compared tirzepatide with semaglutide once weekly and reported greater reductions in HbA1c and body weight in the tirzepatide arms. SURPASS-1 follow-up analysis examined what happened to HbA1c and body weight in the four weeks after treatment stopped, reporting partial reversal of effect.

The SURMOUNT program studied tirzepatide in obesity and overweight. SURMOUNT-1, published in 2022, reported substantial dose-dependent weight reduction over 72 weeks compared with placebo. A pooled analysis of the SURPASS trials characterized gastrointestinal adverse events — nausea, diarrhea, and vomiting most commonly — as the predominant tolerability signal.

These results come from large, supervised, randomized trials using pharmaceutical-grade product in defined patient populations. They are reported here as scientific background only.

Tirzepatide is the active ingredient in FDA-approved prescription medicines: Mounjaro, approved in 2022 for type 2 diabetes, and Zepbound, approved in 2023 for chronic weight management. Approval attaches to those specific manufactured products under their labeling and supply chains.

Research-grade tirzepatide supplied for laboratory use is not one of those products. It is not manufactured, labeled, dispensed, or regulated as a medicine, and the existence of an approved product elsewhere confers nothing on a research material. North Summit Labs supplies this compound strictly for in-vitro laboratory research.

Supplied lyophilized in a sealed vial. Standard peptide practice applies: protect from moisture, light, and heat; equilibrate cold vials before opening; reconstitute with a solvent appropriate to the assay; aliquot to avoid repeated freeze-thaw cycles; and record lot numbers alongside experimental data so results remain traceable to a specific certificate.

This monograph summarizes published scientific literature for educational and reference purposes only. It is not medical, veterinary, clinical, or dosing guidance, and nothing here should be read as a claim that this compound is safe, effective, or approved for use in humans or animals.

Material supplied by North Summit Labs is intended strictly for in-vitro laboratory research by qualified professionals. It is not a drug, supplement, food, cosmetic, or medical device, and it is not for human or animal consumption. Investigators are responsible for complying with their own institutional oversight, biosafety, and legal requirements.